EUVIMEDEUVIMED entdecken
Kohortenstudie

Real‐world effectiveness of sotrovimab and remdesivir for early treatment of high‐risk hospitalized COVID‐19 patients: A propensity score adjusted retrospective cohort study

Lin Pin Koh, Siang Li Chua, Shawn Vasoo, Matthias Paul Han Sim Toh, Jeremy Nicholas Cutter, Puay Hoon Nah, Yee-Sin Leo, Jun Xin Tay, Barnaby Edward Young, David C Lye, Sean W X Ong

Journal of Medical Virology · 2023

DOI: 10.1002/jmv.28460 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Journal of Medical Virology, 2023. Verfasst von Lin Pin Koh und 10 weiteren Autor:innen. Beteiligte Einrichtung: National Centre for Infectious Diseases, Singapore, Singapore. Hauptthemen laut MEDLINE: COVID-19. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: National Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Early treatment of high‐risk COVID‐19 patients may prevent disease progression. However, there are limited data to support treatment of hospitalized or fully vaccinated patients with mild‐to‐moderate disease. In this retrospective cohort study, we studied the effect of early use of sotrovimab and remdesivir in high‐risk hospitalized COVID‐19 patients. We included PCR‐confirmed COVID‐19 patients admitted to the National Centre for Infectious Diseases who presented within the first 5 days of illness, and who were not requiring oxygen or ICU care at presentation. Sotrovimab‐ and remdesivir‐treated groups were compared with control (no early treatment). A multiple propensity‐score adjusted multivariable regression analysis was conducted with a composite primary endpoint of in‐hospital deterioration (oxygen requirement, ICU admission, or mortality). Of 1118 patients, 841 were in the control group, 106 in the sotrovimab group and 169 in the remdesivir group. The median age was 63 years (IQR 46–74 years) and 505 (45.2%) were female. In unvaccinated patients, both remdesivir and sotrovimab treatment were protective (adjusted odds ratio [aOR] 0.19, 95% CI 0.064–0.60 and 0.18 [95% CI 0.066–0.47]), respectively. Contrarily, among the vaccinated patients there was no significant treatment effect with early remdesivir treatment (aOR 2.51, 95% CI 0.83–7.57, p = 0.10). Remdesivir and sotrovimab treatment, given early in the disease course to unvaccinated high‐risk patients, was effective in reducing the risk of in‐hospital deterioration and severe disease. This effect was not seen in fully vaccinated patients, which may be due to a small sample size or residual confounding.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19HumansFemaleMiddle AgedMaleCOVID-19 Drug TreatmentPropensity ScoreRetrospective StudiesDisease ProgressionOxygenAdenosine MonophosphateAlanineAntibodies, NeutralizingAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

COVID-19SARS-CoV-2early-treatmenthigh-riskremdesivirsotrovimab

Substanzen

OxygenremdesivirAdenosine MonophosphateAlaninesotrovimabAntibodies, NeutralizingAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • National Centre for Infectious Diseases, Singapore, Singapore.
  • Anglo-Chinese School (Independent), Singapore, Singapore.
  • Department of Infectious Diseases, Tan Tock Seng Hospital, Singapore, Singapore.
  • Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore.
  • Saw Swee Hock School of Public Health, National University of Singapore, Singapore, Singapore.
  • Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.

Förderung

  • National Medical Research Council

Zitieren

APA

Koh, L. P., Chua, S. L., Vasoo, S., Toh, M. P. H. S., Cutter, J. N., Nah, P. H., Leo, Y. S., Tay, J. X., Young, B. E., Lye, D. C., & Ong, S. W. X. (2023). Real‐world effectiveness of sotrovimab and remdesivir for early treatment of high‐risk hospitalized COVID‐19 patients: A propensity score adjusted retrospective cohort study. Journal of Medical Virology. https://doi.org/10.1002/jmv.28460

Vancouver

Koh LP, Chua SL, Vasoo S, Toh MPHS, Cutter JN, Nah PH, et al. Real‐world effectiveness of sotrovimab and remdesivir for early treatment of high‐risk hospitalized COVID‐19 patients: A propensity score adjusted retrospective cohort study. Journal of Medical Virology. 2023. doi:10.1002/jmv.28460

BibTeX
@article{Koh2023,
  author = {Koh, Lin Pin and Chua, Siang Li and Vasoo, Shawn and Toh, Matthias Paul Han Sim and Cutter, Jeremy Nicholas and Nah, Puay Hoon and Leo, Yee-Sin and Tay, Jun Xin and Young, Barnaby Edward and Lye, David C and Ong, Sean W X},
  title = {Real‐world effectiveness of sotrovimab and remdesivir for early treatment of high‐risk hospitalized COVID‐19 patients: A propensity score adjusted retrospective cohort study},
  journal = {Journal of Medical Virology},
  year = {2023},
  doi = {10.1002/jmv.28460}
}
Kostenlos starten →